Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients

World Journal of Gastroenterology

Volumn 11, Issue 34, 2005, Pages 5283-5288

  Su, Wen Pin ^a   Wen, Chi Chung ^b   Hsiung, Chao A ^b   Su, Ih Jen ^b   Cheng, Ann Lii ^a   Chang, Ming Chih ^c   Tsao, Chao Jung ^d   Kao, Woei Yao ^e   Uen, Wu Ching ^f   Hsu, Chih Hung ^a   Lu, Yen Shen ^a   Tien, Hwei Fan ^a   Chao, Tsu Yi ^e   Chen, Li Tzong ^b   Whang Peng, Jacqueline ^b   Chen, Pei Jer ^g  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

^d CHI MEI MEDICAL CENTER   (Taiwan)

^e TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^f Shin Kong Memorial Hospital   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Chemotherapy; HBV reactivation; Liver function; Non Hodgkin's lymphoma

Indexed keywords

ALBUMIN; CYTOTOXIC AGENT; GLOBULIN; PROTHROMBIN; VIRUS DNA;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; ASCITES; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DATA BASE; DIAGNOSTIC IMAGING; DRUG RESPONSE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B VIRUS; HUMAN; INFECTION; INTERNATIONAL NORMALIZED RATIO; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FUNCTION; LYMPHOMA; MALE; MALNUTRITION; NONHUMAN; PUBLICATION; RISK FACTOR; SPLENOMEGALY; SURVIVAL RATE; VIRUS REACTIVATION; VIRUS TITRATION;

EID: 84983718388     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i34.5283     Document Type: Article

References (34)

1. Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975; 2: 528-530
2. Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 1975; 68: 105-112
3. Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, Costa J. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982; 96: 447-449
4. Thung SN, Gerber MA, Klion F, Gilbert H. Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier. Arch Intern Med 1985; 145: 1313-1314
5. Lau JY, Lai CL, Lin HJ, Lok AS, Liang RH, Wu PC, Chan TK, Todd D. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med 1989; 73: 911-917
6. Pariente EA, Goudeau A, Dubois F, Degott C, Gluckman E, Devergie A, Brechot C, Schenmetzler C, Bernuau J. Fulminant hepatitis due to reactivation of chronic hepatitis B virus infection after allogeneic bone marrow transplantation. Dig Dis Sci 1988; 33: 1185-1191
7. Liang RH, Lok AS, Lai CL, Chan TK, Tood D, Chiu EK. Hepatitis B infection in patients with lymphoma. Hematol Oncol 1990; 8: 261-270
8. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-188
9. Liaw YF. Hepatitis viruses under immunosuppressive agents. J Gastroentrol Hepatol 1998; 13: 14-20
10. Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G. Prevalence of hepatitis B virus marker positivity and evaluation of hepatitis B virus profile, during chemotherapy, in patients with solid tumors. Br J Cancer 1999; 81: 69-74
11. Markovic S, Drozina G, Vovk M, Fidler-Jenko M. Reactivation of hepatitis B but not hepatits C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 1999; 46: 2925-2930
12. Liang R, Lau GK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 1999; 17: 394-398
13. Cheng AL. Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma. Blood 1996; 87: 1202
14. Kumagai K, Takagi T, Nakamura S, Sawada U, Kura Y, Kodama F, Shimano S, Kudoh I, Nakamura H, Sawada K, Ohnoshi T. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 1997: 8(Suppl 1): 107-109
15. Faggiolli P, De Paschale M, Tocci A, Luoni M, Fava S, De Pali A, Tosi A, Cassi E. Acute hepatic toxicity during cyclic chemotherapy in non-Hodgkin's lymphoma. Hematologica 1997; 82: 38-42
16. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120: 1009-1022
17. Cheng AL, Hsiung CA, Su IJ, Chen PJ, Chang MC, Tsao CJ, Kao WY, Uen WC, Hsu CH, Tien HF, Chao TY, Chen LT, Wang-Peng J. Lymphoma Committee of Taiwan Cooperative Oncology Group. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003; 37: 1320-1328
18. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118: 554-559
19. Triger DR, Wright R. Hyperglobulinaemia in liver disease. Lancet 1973; 1: 1494-1496
20. Czaja AJ, Wolf AM, Baggenstoss AH. Clinical assessment of cirrhosis in severe chronic active liver disease: specificity and sensitivity of physical and laboratory findings. Mayo Clin Proc 1980; 55: 360-364
21. Lin DY, Liaw YF, Chu CM, Chang-Chien CS, Wu CS, Chen PC, Sheen IS. Hepatocellular carcinoma in noncirrhosis patients. A laparoscopic study of 92 cases in Taiwan. Cancer 1984; 54: 1466-1468
22. Luo JC, Hwang SJ, Chang FY, Chu CW, Lai CR, Wang YJ, Lee PC, Tsay SH, Lee SD. Simple blood tests can predict compensated liver cirrhosis in patients with chronic hepatitis C. Hepatogastroenterology 2002; 49: 478-481
23. Schlichting P, Christensen E, Andersen PK, Fauerholdt L, Juhl E, Poulsen H, Tygstrup N. Prognostic factors in cirrhosis identified by Cox's regression model. Hepatology 1983; 3: 889-895
24. Oberti F, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Aubé C, Gallois Y, Rifflet H, Maiga MY, Penneau-Fontbonne D, Cales P. Noninvasive Diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997; 113: 1609-1616
25. Nagamatsu H, Kumashiro R, Itano S, Matsugaki S, Sata M. Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCC. Hepatol Res 2003; 26: 293-301
26. Christensen E, Schlichting P, Fauerholdt L, Gluud C, Andersen PK, Juhl E, Poulsen H, Tygstrup N. Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. Hepatology 1984; 4: 430-435
27. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 2003; 23: 47-58
28. Kao JH. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002; 17: 643-650
29. Liu CJ, Kao JH, Chen PJ, Lai MY, Chen DS. Molecular epidemiology of hepatitis B viral serotypes and genotypes in Taiwan. J Biomed Sci 2002; 9: 166-170
30. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion. in Taiwanese hepatitis B carriers. J Med Virol 2004; 72: 363-369
31. Grandjacques C, Pradat P, Stuyver L, Chevallier M, Chevallier P, Pichoud C, Maisonnas M, Trepo C, Zoulim F. Rapid detection of genotypes and mutations in the pre-core promotor and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol 2000; 33: 430-439
32. Rodriguez-Frias F, Buti M, Jardi R, Cotrina M, Viladomiu L, Esteban R, Guardia J. Hepatitis B virus infection: precore mutants and its relation to viral genotypes and core mutations. Hepatology 1995; 22: 1641-1647
33. Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, Cheung M, Zhang HY, Lie A, Ngan R, Liang R. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 1742-1749
34. Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI, Chan AT, Mok TS, Lee JJ, Leung TW, Zhong S, Johnson PJ. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004; 22: 927-934